Skip to main content

DOSING

 Dose Reduction Schedule Dose Reduction Schedule Dose Modification Guidelines Preparation & Administration Preparation & Administration Dose Modifications

TO HELP PATIENTS STAY ON TREATMENT, UTILIZE DOSE MODIFICATIONS1

Dose reduction schedule

Adjust the dose while maintaining a 3-week interval between doses1

Recommended dose reduction schedule for ARs1
  ELAHERE dose level
Starting dose 6 mg/kg AIBW q3w (21-day cycle)
First dose reduction 5 mg/kg AIBW q3w (21-day cycle)
Second dose reduction 4 mg/kg AIBW q3w (21-day cycle)*

*Permanently discontinue in patients who cannot tolerate 4 mg/kg AIBW.1
AR=adverse reaction; AIBW=adjusted ideal body weight; q3w=every 3 weeks.

Dose modification guidelines

Recommended dose modification guidelines for ocular ARs1
Adverse reaction Severity of adverse reaction† Dosage modification
Keratitis/keratopathy Nonconfluent superficial keratitis Monitor
Confluent superficial keratitis, a corneal epithelial defect, or 3-line or more loss in best-corrected visual acuity Withhold until improved or resolved, then maintain at same dose level or consider dose reduction
Corneal ulcer or stromal opacity or best-corrected distance visual acuity 20/200 or worse Withhold until improved or resolved, then reduce by 1 dose level
Corneal perforation Permanently discontinue
Uveitis Grade 1: Rare cell in anterior chamber Monitor
Grade 2: 1 to 2+ cell or flare in anterior chamber Withhold until Grade 1 or less, then maintain dose at same dose level
Grade 3: 3+ cell or flare in anterior chamber Withhold until Grade 1 or less, then reduce dose by 1 dose level
Grade 4: Hypopyon Permanently discontinue

†Unless otherwise specified, National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0.1

Your patient's eye care provider will monitor for ocular ARs and should notify you if any occur

Your patient's eye care provider will monitor for ocular ARs and should notify you if any occur
Recommended dose modification guidelines for other ARs1
Adverse reaction Severity of adverse reaction‡ Dosage modification
Pneumonitis Grade 1 Monitor
Grade 2 Withhold until Grade 1 or less, then maintain at same dose level or consider dose reduction
Grade 3 or 4 Permanently discontinue
Peripheral neuropathy Grade 2 Withhold until Grade 1 or less, then reduce by 1 dose level
Grade 3 or 4 Permanently discontinue
Infusion-related reactions/ hypersensitivity Grade 1 Maintain infusion rate
Grade 2
  • Interrupt infusion and administer supportive treatment
  • After recovery from symptoms, resume the infusion at 50% of the previous rate, and if no further symptoms appear, increase rate as appropriate until infusion is completed
  • Administer additional premedication for future cycles
Grade 3 or 4
  • Immediately stop infusion and administer supportive treatment
  • Advise patient to seek emergency treatment and immediately notify their healthcare provider if the infusion-related symptoms recur
  • Permanently discontinue
Hematological Grade 3 or 4 Withhold until Grade 1 or less, then resume at 1 lower dose level
Other adverse reactions Grade 3 Withhold until Grade 1 or less, then resume at 1 lower dose level
Grade 4 Permanently discontinue

‡Unless otherwise specified, NCI CTCAE version 5.0.1

Dosing information on demand

The Dosing and Administration Booklet provides
easy-to-access information about how ELAHERE is
dosed and administered. DOWNLOAD BOOKLET

Need ordering information?

The ELAHERE Ordering Information Sheet has a list
of participating specialty distributors and specialty
pharmacy partners. DOWNLOAD THE LIST
  1. ELAHERE. Package insert. AbbVie; 2025.